Wisconsin | Articles

Settlements Reached in Neurontin (Gabapentin) Cases


Get Help Now


Illegal off-label marketing of gabapentin led to significant penalties for the manufacturer

It has been more than twenty years since the U.S. Food and Drug Administration (FDA) approved Neurontin (gabapentin) for the treatment of epilepsy in the United States. Since then, the FDA has expanded the approval of Neurontin to treat a complication of shingles known as postherpetic neuralgia.

But the Drug Has Been Prescribed for Much More Than That

Neurontin is allegedly routinely prescribed to treat conditions for which the drug has never received FDA approval. Some of those conditions include:

  • Migraines.
  • Bipolar disorder.
  • Pain.
  • Other conditions.

When a drug is prescribed for a condition for which it does not have FDA approval it is known as an “off-label” prescription. While it is legal for a doctor to write an off-label prescription, it is illegal for a drug manufacturer to market its drug for an off-label use.

Pfizer, the drug manufacturer of Neurontin, has been accused of marketing the drug for off-label prescriptions.

Why This Is Dangerous for Patients

Neurontin has been linked to serious side effects, including depression and suicidal thoughts. While the FDA has reviewed studies that weigh the benefits of Neurontin against the potential side effects for the treatment of epilepsy and shingles pain, it has not reviewed similar studies for the treatment of other conditions. Thus, the risks of depression and suicide may outweigh the potential benefits from the medication, and patients’ lives may be ruined—or ended—because of these side effects.

If you have questions about the safety of this drug, then we encourage you to talk to your doctor about your options.

Pfizer Pays Damages

In 2004, Pfizer pleaded guilty to advertising the drug for non-FDA approved uses and reached a settlement worth approximately $430 million with the U.S. Justice Department.

In April 2014, agreed to a $190 million settlement in a class action suit with consumers. In June 2014, Pfizer reached another class action settlement of about $325 million for the off-label marketing of Neurontin.

While Gabapentin lawsuits have been settled, many people suffer serious injuries from other specific drugs. If this has happened to you then we encourage you to speak to your doctor and to one of our attorneys as soon as possible to learn more about your rights. Please contact us online or call us directly at 800.800.5678 for your free consultation.

Jason F. Abraham
Managing Partner, Hupy and Abraham

Free Offers

Get Your FREE "DNT TXT N DRV" Bumper Sticker!

Get Your FREE "DNT TXT N DRV" Bumper Sticker!

Request your FREE “DNT TXT N DRV” bumper sticker and help the Wisconsin car accident attorneys at Hupy and Abraham raise awareness of distracted driving.

View Details